List of Antibody Drug Conjugates Companies in Taiwan - 5

GlycoNex Inc. was founded in 2001, in alliance with The Biomembrane Institute (TBI) from Washington University and Dr. Sen-Itiroh Hakomori, a member of the National Academy of Sciences (USA). GlycoNex was the first pharmaceutical company in Taiwan to combine cancer-related glycan identification with human monoclonal antibody development. GlycoNex Inc. possesses a complete and detailed technological platform for anti-glycan antibody development, including multiple acquired licensed patents. Our pipeline consists of new drug development in parallel with biosimilars. Our new drugs were selected and developed through a detailed antigen/antibody characterization and cell line development. In 2009, we licensed GNX8 to Otsuka Pharmaceutical Co., Ltd. In 2019, our first-in-class new drug GNX102 received FDA IND approval. In 2020, we initiated our Clinical Trial Phase I dose-escalation study for GNX102 and received TFDA IND approval. In parallel, our biosimilar products Denosumab and Aflibercept have completed different volumes of pilot studies and data ready for review. We aim to look for opportunities of out-licensing our products or co-develop in cooperation.

HuniLife Biotechnology, Inc. is a Taiwan-based biopharmaceutical company founded in 2013. HuniLife strives to develop efficacious new drugs and treatments to improve human health and well-being. The company focuses on drug pipelines, patents, clinical trials, and investment in the biopharmaceutical industry.

Immunwork, Inc. is a privately held biotech company focusing on the research, development, and commercialization of novel drugs to fulfill unmet medical needs. Our drugs are created based on our proprietary technology platform for treating multiple types of cancer, diabetes, obesity, non-alcoholic steatohepatitis (NASH), pathological blood clots, and other selected severe clinical conditions. Our unique platform allows us to design and generate novel “T-E” drug molecules, which contain targeting (T) and effector (E) moieties. These designs would help to improve the efficacy and limit toxicity. The majority of our T-E drugs are based on “multi-arm linkers” and various “drug bundles”. These drug candidates include antibody-drug conjugates (ADCs), antibody-radionuclide conjugates (ARCs), ultra-long-acting therapeutic peptides, and drugs in other modalities. Six of the drug candidates have been selected and progressed into the pre-clinical development stage. Meanwhile, we are looking forward to applying the multi-arm linker platform for designing additional novel drug candidates.

OBI Pharma, Inc. is a Taiwan based bio-pharma company founded in 2002. Our mission is to improve health and the quality of life through innovative cancer therapeutics. We seek to develop and license novel therapeutic agents for unmet medical needs against cancer by targeting the Globo Series antigens (Globo H, SSEA-4), the AKR1C3 enzyme, and other promising targets. Our leading compound is Adagloxad simolenin, a late-stage novel active immuno-oncology (IO) Globo Series-based therapeutic vaccine for the treatment of epithelial cancers, such as breast, ovarian, lung, prostate, colon, gastric, and pancreatic cancer. OBI has a full spectrum of Globo Series IO pipeline, which includes both active (vaccine) and passive (monoclonal antibody & antibody drug conjugate) therapeutics. Development of OBI-888 (Globo H monoclonal antibody), OBI-833 (Globo Series vaccine) for epithelial cancers, OBI-999 (Globo H antibody drug conjugate), OBI-898 (SSEA-4 monoclonal antibody), and OBI-866 (SSEA-4 vaccine) for multiple cancers are also underway. In addition, development of OBI-3424, a novel First-in-Class compound targeting both solid and liquid that express the Aldo Keto Reductase 1C3 enzyme, further enriches the company’s pipeline profile. OBI Pharma, Inc. is publicly listed on the Taipei Exchange (TPEx: 4174); wholly-owned subsidiaries are present in the United States and China. The company is led by management team with a track record of success in new drug development and commercialization.

Noticing that antibody drugs can effectively cure diseases but at the same time cause severe adverse effects because of on-target toxicity, PrecisemAb, just like our name "Precise + mAb", is committed to creating the safest antibody therapy for patients. Our Universal Antibody Lock technology could "inactivate" antibody's binding ability by giving it a "Lock" on the biding site. The binding ability of antibody is limited in healthy tissues unless antibody encounters disease-associated protease in the diseased site. The cleaved Lock-antibody is designed to be specifically activated and neutralize the target antigen to inhibit the disease progression. Therefore, our antibody lock technology can effectively enhance antibody drugs’ selectivity in disease area and consequently reduce side effects caused by on-target toxicity. We at PrecisemAb deeply believe in scientific thinking and cultural diversity since innovations always come from diversity, and scientific mind can transform creativities into practical solutions. This belief is not only applied to how we work internally but also how we collaborate with external partners and how we contribute back to our society.